Search research articles
Contact Us
Filters
Showing results (291-300 of 392) with videos related to
Page
of 40
Sort By:
ESMO Open
|
June 2, 2022
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
E Laakmann, I Witzel, T Neunhöffer, et al.
ESMO Open
|
April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
K Riecke, V Müller, T Neunhöffer, et al.
Journal of Veterinary Emergency and Critical Care (San Antonio, Tex. : 2001)
|
October 20, 2010
European outbreak of atypical myopathy in the autumn 2009
Gaby Van Galen, Helene Amory, Evita Busschers, et al.
ESMO Open
|
November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
V Müller, M Banys-Paluchowski, T W P Friedl, et al.
ESMO Open
|
March 22, 2025
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay
W Janni, B Rack, T W P Friedl, et al.
British Journal of Cancer
|
August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
I Witzel, S Loibl, G von Minckwitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis
M Untch, G von Minckwitz, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery
M Untch, P A Fasching, G E Konecny, et al.
BMC Cancer
|
December 18, 2015
Partial PTEN deletion is linked to poor prognosis in breast cancer
P Lebok, V Kopperschmidt, M Kluth, et al.
Page
of 40
Search research articles
Search
Showing results (291-300 of 392) with videos related to
Sort By:
Page
of 40
ESMO Open
|
June 2, 2022
Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry
E Laakmann, I Witzel, T Neunhöffer, et al.
ESMO Open
|
April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry
K Riecke, V Müller, T Neunhöffer, et al.
Journal of Veterinary Emergency and Critical Care (San Antonio, Tex. : 2001)
|
October 20, 2010
European outbreak of atypical myopathy in the autumn 2009
Gaby Van Galen, Helene Amory, Evita Busschers, et al.
ESMO Open
|
November 28, 2021
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
V Müller, M Banys-Paluchowski, T W P Friedl, et al.
ESMO Open
|
March 22, 2025
Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay
W Janni, B Rack, T W P Friedl, et al.
British Journal of Cancer
|
August 16, 2012
Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
I Witzel, S Loibl, G von Minckwitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 9, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis
M Untch, G von Minckwitz, G E Konecny, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2014
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy
J L Lindner, S Loibl, C Denkert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 10, 2011
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery
M Untch, P A Fasching, G E Konecny, et al.
BMC Cancer
|
December 18, 2015
Partial PTEN deletion is linked to poor prognosis in breast cancer
P Lebok, V Kopperschmidt, M Kluth, et al.
Page
of 40